WASHINGTON, Aug. 4-Medicare is about to announce that beginning in October it will start paying hospitals for use of the thrombolytic drug tissue plasminogen activator (tPA) for treatment of ischemic ...

The American Heart Association/American Stroke Association has issued a new scientific statement on the rationale for the inclusion and exclusion criteria for intravenous alteplase (tissue plasminogen ...

A new analysis suggests that about a quarter of potentially eligible patients are not receiving thrombolysis for ischemic stroke, and some of the reasons for this might be modifiable, researchers say.

Standard practice dictates that all eligible patients receive IV thrombolysis before undergoing endovascular treatment of an acute ischemic stroke caused by a large vessel occlusion, but a new ...

Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered. The finding ...

Commenting on the study's results, lead author Robert J. Adams, MD, said, "Having sickle cell disease did not adversely affect any of the indicators we measured." New research has found that tissue ...

Tissue plasminogen activator (tPA) is a medication that doctors administer following a stroke caused by a blood clot. It breaks up the blood clot to allow blood flow to return to the brain. The ...

Thrombolysis with tissue plasminogen activator (tPA) in acute ischemic stroke can increase the risks of hemorrhage formation and reperfusion injury. The pathogenesis of hemorrhage formation after ...

Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered. The finding ...

Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered. The finding ...